These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27563673)

  • 21. From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.
    Gharib E; Robichaud GA
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemosensitivity analysis and study of gene resistance on tumors and cancer stem cell isolates from patients with colorectal cancer.
    Garza-Treviño EN; Martínez-Rodríguez HG; Delgado-González P; Solís-Coronado O; Ortíz-Lopez R; Soto-Domínguez A; Treviño VM; Padilla-Rivas GR; Islas-Cisneros JF; Quiroz-Reyes AG; Said-Fernández SL
    Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LncRNA LINC01116 Promotes the Development of Colorectal Cancer by Targeting miR-9-5p/STMN1.
    Bi C; Cui H; Fan H; Li L
    Onco Targets Ther; 2020; 13():10547-10558. PubMed ID: 33116633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC).
    Pang SW; Awi NJ; Armon S; Lim WW; Low JS; Peh KB; Peh SC; Teow SY
    Diagnostics (Basel); 2019 Dec; 10(1):. PubMed ID: 31877940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients.
    Labriet A; Lévesque É; Cecchin E; De Mattia E; Villeneuve L; Rouleau M; Jonker D; Couture F; Simonyan D; Allain EP; Buonadonna A; D'Andrea M; Toffoli G; Guillemette C
    Sci Rep; 2019 Sep; 9(1):13008. PubMed ID: 31506518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological and prognostic significance of leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) in malignant tumors: A meta-analysis.
    Zhang Q; Shi W; Wang Q; Zhu Y; Zhai C; Wang J; Yan X; Chai L; Li M
    J Cancer; 2018; 9(16):2895-2909. PubMed ID: 30123358
    [No Abstract]   [Full Text] [Related]  

  • 27. A cross-talk between integrin β4 and epidermal growth factor receptor induces gefitinib chemoresistance to gastric cancer.
    Huafeng J; Deqing Z; Yong D; Yulian Z; Ailing H
    Cancer Cell Int; 2018; 18():50. PubMed ID: 29618949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of EZH2 in overall survival of colorectal cancer: a meta-analysis.
    Vilorio-Marqués L; Martín V; Diez-Tascón C; González-Sevilla MF; Fernández-Villa T; Honrado E; Davila-Batista V; Molina AJ
    Sci Rep; 2017 Oct; 7(1):13806. PubMed ID: 29061982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs.
    Lizarbe MA; Calle-Espinosa J; Fernández-Lizarbe E; Fernández-Lizarbe S; Robles MÁ; Olmo N; Turnay J
    Biomed Res Int; 2017; 2017():7354260. PubMed ID: 28573140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling
    Su T; Bai JX; Chen YJ; Wang XN; Fu XQ; Li T; Guo H; Zhu PL; Wang Y; Yu ZL
    Front Pharmacol; 2017; 8():227. PubMed ID: 28503147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis.
    Dendy MS; Ludwig JM; Kim HS
    Oncotarget; 2017 Jun; 8(23):37912-37922. PubMed ID: 28415671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.
    Kim DY; Paek TY; Oh SY; Kim YB; Lee JH; Lee MY; Choi ZS; Suh KW
    J Surg Oncol; 2014 Mar; 109(3):250-4. PubMed ID: 24318863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options.
    Rodrigues D; Longatto-Filho A; Martins SF
    Biomed Res Int; 2016; 2016():6896024. PubMed ID: 27563673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer Stem Cells and Molecular Biology Test in Colorectal Cancer: Therapeutic Implications.
    Effendi-Ys R
    Acta Med Indones; 2017 Oct; 49(4):351-359. PubMed ID: 29348387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer.
    Xie T; Huang M; Wang Y; Wang L; Chen C; Chu X
    Cell Physiol Biochem; 2016; 40(1-2):62-76. PubMed ID: 27842308
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.